Furfenorex

Furfenorex is a stimulant drug that was developed in the 1960s for the treatment of obesity. It is chemically related to amphetamine and other psychostimulant drugs and has similar effects on the body, including increased heart rate, increased blood pressure, and suppression of appetite.

Chemistry[edit | edit source]

Furfenorex is a derivative of phenethylamine, a naturally occurring substance found in the human body and in many foods. It is structurally similar to amphetamine, but has a furan ring attached to the alpha carbon atom. This modification increases the drug's potency and duration of action.

Pharmacology[edit | edit source]

Furfenorex acts primarily as a norepinephrine-dopamine reuptake inhibitor, meaning it increases the levels of these neurotransmitters in the brain by preventing their reabsorption into the neurons. This results in increased stimulation of the central nervous system, leading to the drug's stimulant effects.

Medical uses[edit | edit source]

Furfenorex was used as an anorectic drug in the treatment of obesity. It was marketed under the brand name Fenopront in some countries, but has since been withdrawn from the market due to concerns about its potential for abuse and addiction.

Side effects[edit | edit source]

Common side effects of furfenorex include insomnia, restlessness, and increased heart rate. More serious side effects can include psychosis, cardiovascular disease, and dependence.

Legal status[edit | edit source]

Furfenorex is currently classified as a Schedule III drug under the Convention on Psychotropic Substances, meaning it has a potential for abuse but also has accepted medical uses.